ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. **NAME OF THE MEDICINAL PRODUCT**

ABASAGLAR 100 units/mL solution for injection in a cartridge

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each mL contains 100 units insulin glargine* (equivalent to 3.64 mg).

Each cartridge contains 3 mL of solution for injection, equivalent to 300 units.

* Insulin glargine is produced by recombinant DNA technology in *Escherichia coli*.

For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Solution for injection. (Injection).

Clear, colourless solution.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.

4.2 **Posology and method of administration**

**Posology**

ABASAGLAR contains insulin glargine, an insulin analogue and has a prolonged duration of action.

ABASAGLAR should be administered once daily at any time but at the same time each day.

The ABASAGLAR dose regimen (dose and timing) should be individually adjusted. In patients with type 2 diabetes mellitus, ABASAGLAR can also be given together with orally active antidiabetic medicinal products.

The potency of this medicinal product is stated in units. These units are exclusive to insulin glargine and are not the same as IU or the units used to express the potency of other insulin analogues (see section 5.1).

**Special populations**

Elderly population (≥65 years old)

In the elderly, progressive deterioration of renal function may lead to a steady decrease in insulin requirements.
Renal impairment
In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.

Hepatic impairment
In patients with hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.

Paediatric population
Safety and efficacy of insulin glargine have been established in adolescents and children aged 2 years and older. Currently available data are described in sections 4.8, 5.1 and 5.2.

Safety and efficacy of insulin glargine have not been established in children below the age of 2 years. No data are available.

Transition from other insulins to ABASAGLAR
When changing from a treatment regimen with an intermediate or long-acting insulin to a regimen with ABASAGLAR, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast-acting insulin analogues or the dose of oral antidiabetic medicinal products).

To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with ABASAGLAR should reduce their daily dose of basal insulin by 20-30 % during the first weeks of treatment.

During the first weeks the reduction should, at least partially, be compensated by an increase in mealtime insulin, after this period the regimen should be adjusted individually.

As with other insulin analogues, patients with high insulin doses because of antibodies to human insulin may experience an improved insulin response with ABASAGLAR.

Close metabolic monitoring is recommended during the transition and in the initial weeks thereafter. With improved metabolic control and resulting increase in insulin sensitivity a further adjustment in dose regimen may become necessary. Dose adjustment may also be required, for example, if the patient's weight or life-style changes, change of timing of insulin dose or other circumstances arise that increase susceptibility to hypoglycaemia or hyperglycaemia (see section 4.4).

Method of administration
ABASAGLAR is administered subcutaneously.

ABASAGLAR should not be administered intravenously. The prolonged duration of action of insulin glargine is dependent on its injection into subcutaneous tissue. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycaemia.

There are no clinically relevant differences in serum insulin or glucose levels after abdominal, deltoid or thigh administration of insulin glargine. Injection sites must be rotated within a given injection area from one injection to the next.

ABASAGLAR must not be mixed with any other insulin or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation.

For further details on handling, see section 6.6.

4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use

ABASAGLAR is not the insulin of choice for the treatment of diabetic ketoacidosis. Instead, regular insulin administered intravenously is recommended in such cases.

In case of insufficient glucose control or a tendency to hyperglycaemic or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.

Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (regular, NPH, lente, long-acting, etc.), origin (animal, human, human insulin analogue) and/or method of manufacture may result in the need for a change in dose.

Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see section 4.8).

Hypoglycaemia

The time of occurrence of hypoglycaemia depends on the action profile of the insulins used and may, therefore, change when the treatment regimen is changed. Due to more sustained basal insulin supply with insulin glargine, less nocturnal but more early morning hypoglycaemia can be expected.

Particular caution should be exercised, and intensified blood glucose monitoring is advisable in patients in whom hypoglycaemic episodes might be of particular clinical relevance, such as in patients with significant stenoses of the coronary arteries or of the blood vessels supplying the brain (risk of cardiac or cerebral complications of hypoglycaemia) as well as in patients with proliferative retinopathy, particularly if not treated with photocoagulation (risk of transient amaurosis following hypoglycaemia).

Patients should be aware of circumstances where warning symptoms of hypoglycaemia are diminished. The warning symptoms of hypoglycaemia may be changed, be less pronounced or be absent in certain risk groups. These include patients:
- in whom glycaemic control is markedly improved,
- in whom hypoglycaemia develops gradually,
- who are elderly,
- after transfer from animal insulin to human insulin,
- in whom an autonomic neuropathy is present,
- with a long history of diabetes,
- suffering from a psychiatric illness,
- receiving concurrent treatment with certain other medicinal products (see section 4.5).

Such situations may result in severe hypoglycaemia (and possibly loss of consciousness) prior to the patient's awareness of hypoglycaemia.

The prolonged effect of subcutaneous insulin glargine may delay recovery from hypoglycaemia.

If normal or decreased values for glycated haemoglobin are noted, the possibility of recurrent, unrecognised (especially nocturnal) episodes of hypoglycaemia must be considered.

Adherence of the patient to the dose and dietary regimen, correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia. Factors increasing the susceptibility to hypoglycaemia require particularly close monitoring and may necessitate dose adjustment. These include:
- change in the injection area,
- improved insulin sensitivity (e.g., by removal of stress factors),
- unaccustomed, increased or prolonged physical activity,
- intercurrent illness (e.g. vomiting, diarrhoea),
- inadequate food intake,
- missed meals,
- alcohol consumption,
- certain uncompensated endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or adrenocortical insufficiency),
- concomitant treatment with certain other medicinal products.

**Intercurrent illness**

Intercurrent illness requires intensified metabolic monitoring. In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin requirement is often increased. Patients with type 1 diabetes must continue to consume at least a small amount of carbohydrates on a regular basis, even if they are able to eat only little or no food, or are vomiting etc. and they must never omit insulin entirely.

**Pens to be used with ABASAGLAR cartridges**

The cartridges should only be used in conjunction with a reusable pen recommended for the use with Lilly insulin cartridges and should not be used with any other reusable pen as the dosing accuracy has not been established with other pens.

**Medication errors**

Medication errors have been reported in which other insulins, particularly short-acting insulins, have been accidentally administered instead of insulin glargine. Insulin label must always be checked before each injection to avoid medication errors between ABASAGLAR and other insulins.

**Combination of ABASAGLAR with pioglitazone**

Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and ABASAGLAR is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.

**Excipients**

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e., essentially “sodium-free”.

**4.5 Interaction with other medicinal products and other forms of interaction**

A number of substances affect glucose metabolism and may require dose adjustment of insulin glargine.

Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates, somatostatin analogues and sulphonamide antibiotics.

Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens, progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors.
Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood-glucose lowering effect of insulin. Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia.

In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine and reserpine, the signs of adrenergic counter-regulation may be reduced or absent.

4.6 Fertility, pregnancy and lactation

Pregnancy

For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available. A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine.

Animal data do not indicate reproductive toxicity.

The use of ABASAGLAR may be considered during pregnancy, if necessary.

It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy to prevent adverse outcomes associated with hyperglycaemia. Insulin requirements may decrease during the first trimester and generally increase during the second and third trimesters. Immediately after delivery, insulin requirements decline rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose control is essential.

Breast-feeding

It is unknown whether insulin glargine is excreted in human milk. No metabolic effects of ingested insulin glargine on the breastfed newborn/infant are anticipated since insulin glargine as a peptide is digested into amino acids in the human gastrointestinal tract.

Breast-feeding women may require adjustments in insulin dose and diet.

Fertility

Animal studies do not indicate direct harmful effects with respect to fertility.

4.7 Effects on ability to drive and use machines

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machines).

Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. This is particularly important in those who have reduced or absent awareness of the warning symptoms of hypoglycaemia or have frequent episodes of hypoglycaemia. It should be considered whether it is advisable to drive or operate machines in these circumstances.

4.8 Undesirable effects

Summary of safety profile

Hypoglycaemia, in general the most frequent adverse reaction of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement.
Tabulated list of adverse reactions

The following related adverse reactions from clinical trials are listed below as MedDRA preferred term by system organ class and in order of decreasing incidence (very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1,000; very rare: <1/10,000).

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

<table>
<thead>
<tr>
<th>MedDRA system organ classes</th>
<th>Very common</th>
<th>Common</th>
<th>Uncommon</th>
<th>Rare</th>
<th>Very rare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune system disorders</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Allergic reactions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypoglycaemia</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysgeusia</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Eyes disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visual impairment</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Retinopathy</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipohypertrophy</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipatrophy</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myalgia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injection site reactions</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Oedema</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

Description of selected adverse reactions

Metabolism and nutrition disorders
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage. Prolonged or severe hypoglycaemic episodes may be life-threatening. In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter-regulation. Generally, the greater and more rapid the decline in blood glucose, the more marked is the phenomenon of counter-regulation and its symptoms.

Immune system disorders
Immediate-type allergic reactions to insulin are rare. Such reactions to insulin (including insulin glargine) or the excipients may, for example, be associated with generalised skin reactions, angio-oedema, bronchospasm, hypotension and shock, and may be life-threatening.

Insulin administration may cause insulin antibodies to form. In clinical studies, antibodies that cross-react with human insulin and insulin glargine were observed with the same frequency in both NPH-insulin and insulin glargine treatment groups. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia.

Eyes disorders
A marked change in glycaemic control may cause temporary visual impairment, due to temporary alteration in the turgidity and refractive index of the lens.
Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy. However, intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy. In patients with proliferative retinopathy, particularly if not treated with photocoagulation, severe hypoglycaemic episodes may result in transient amaurosis.

**Skin and subcutaneous tissue disorders**

As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions.

**General disorders and administration site conditions**

Injection site reactions include redness, pain, itching, hives, swelling, or inflammation. Most minor reactions to insulins at the injection site usually resolve in a few days to a few weeks.

Rarely, insulin may cause sodium retention and oedema particularly if previously poor metabolic control is improved by intensified insulin therapy.

**Paediatric population**

In general, the safety profile for children and adolescents (≤ 18 years of age) is similar to the safety profile for adults. The adverse reaction reports received from post marketing surveillance included relatively more frequent injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) in children and adolescents (≤ 18 years of age) than in adults. Clinical study safety data are not available for children under 2 years.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

**4.9 Overdose**

**Symptoms**

Insulin overdose may lead to severe and sometimes long-term and life-threatening hypoglycaemia.

**Management**

Mild episodes of hypoglycaemia can usually be treated with oral carbohydrates. Adjustments in dose of the medicinal product, meal patterns, or physical activity may be needed.

More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Drugs used in diabetes, insulins and analogues for injection, long-acting.

ATC Code: A10AE04.

**Mechanism of action**

Insulin glargine is a human insulin analogue designed to have a low solubility at neutral pH. It is completely soluble at the acidic pH of the ABASAGLAR injection solution (pH 4). After injection into the subcutaneous tissue, the acidic solution is neutralised leading to formation of micro-precipitates from which small amounts of insulin glargine are continuously released, providing a smooth, peakless, predictable concentration/time profile with a prolonged duration of action.

Insulin glargine is metabolised into 2 active metabolites M1 and M2 (see section 5.2).

*Insulin receptor binding*

*In vitro* studies indicate that the affinity of insulin glargine and its metabolites M1 and M2 for the human insulin receptor is similar to the one of human insulin.

IGF-1 receptor binding: The affinity of insulin glargine for the human IGF-1 receptor is approximately 5 to 8-fold greater than that of human insulin (but approximately 70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1 receptor with slightly lower affinity compared to human insulin.

The total therapeutic insulin concentration (insulin glargine and its metabolites) found in type 1 diabetic patients was markedly lower than what would be required for a half maximal occupation of the IGF-1 receptor and the subsequent activation of the mitogenic-proliferative pathway initiated by the IGF-1 receptor. Physiological concentrations of endogenous IGF-1 may activate the mitogenic-proliferative pathway; however, the therapeutic concentrations found in insulin therapy, including in ABASAGLAR therapy, are considerably lower than the pharmacological concentrations required to activate the IGF-1 pathway.

**Pharmacodynamic effects**

The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis and enhances protein synthesis.

In clinical pharmacology studies, intravenous insulin glargine and human insulin have been shown to be equipotent when given at the same doses. As with all insulins, the time course of action of insulin glargine may be affected by physical activity and other variables.

In euglycaemic clamp studies in healthy subjects or in patients with type 1 diabetes, the onset of action of subcutaneous insulin glargine was slower than with human NPH insulin, its effect profile was smooth and peakless, and the duration of its effect was prolonged.

The following graph shows the results from a study in patients:
Figure 1: Activity profile in patients with type 1 diabetes

* Determined as amount of glucose infused to maintain constant plasma glucose levels (hourly mean values)

The longer duration of action of subcutaneous insulin glargine is directly related to its slower rate of absorption and supports once daily administration. The time course of action of insulin and insulin analogues such as insulin glargine may vary considerably in different individuals or within the same individual.

In a clinical study, symptoms of hypoglycaemia or counter-regulatory hormone responses were similar after intravenous insulin glargine and human insulin both in healthy volunteers and patients with type 1 diabetes.

Clinical safety and efficacy

Effects of insulin glargine (once daily) on diabetic retinopathy were evaluated in an open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2 diabetic patients in which progression of retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by fundus photography. No significant difference was seen in the progression of diabetic retinopathy when insulin glargine was compared to NPH insulin.

The ORIGIN (Outcome Reduction with Initial Glargine INtervention) study was a multicenter, randomized, 2x2 factorial design study conducted in 12,537 participants at high cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus treated with ≤1 antidiabetic oral agent (88% of participants). Participants were randomized (1:1) to receive insulin glargine (n=6264), titrated to reach FPG ≤95 mg/dL (5.3 mM), or standard care (n=6273). The first co-primary efficacy outcome was the time to the first occurrence of CV death, nonfatal myocardial infarction (MI), or nonfatal stroke, and the second co-primary efficacy outcome was the time to the first occurrence of any of the first co-primary events, or revascularisation procedure (coronary, carotid, or peripheral), or hospitalisation for heart failure.

Secondary endpoints included all-cause mortality and a composite microvascular outcome.

Insulin glargine did not alter the relative risk for CV disease and CV mortality when compared to standard of care. There were no differences between insulin glargine and standard care for the two co-primary outcomes; for any component endpoint comprising these outcomes; for all-cause mortality; or for the composite microvascular outcome.
Mean dose of insulin glargine by study end was 0.42 U/kg. At baseline, participants had a median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9 to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care group throughout the duration of follow-up. The rates of severe hypoglycaemia (affected participants per 100 participant years of exposure) were 1.05 for insulin glargine and 0.30 for standard care group and the rates of confirmed non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard care group. Over the course of this 6-year study, 42% of the insulin glargine group did not experience any hypoglycaemia.

At the last on-treatment visit, there was a mean increase in body weight from baseline of 1.4 kg in the insulin glargine group and a mean decrease of 0.8 kg in the standard care group.

**Paediatric population**

In a randomised, controlled clinical study, paediatric patients (age range 6 to 15 years) with type 1 diabetes (n=349) were treated for 28 weeks with a basal-bolus insulin regimen where regular human insulin was used before each meal. Insulin glargine was administered once daily at bedtime and NPH human insulin was administered once or twice daily. Similar effects on glycohaemoglobin and the incidence of symptomatic hypoglycaemia were observed in both treatment groups, however fasting plasma glucose decreased more from baseline in the insulin glargine group than in the NPH group. There was less severe hypoglycaemia in the insulin glargine group as well. One hundred forty three of the patients treated with insulin glargine in this study continued treatment with insulin glargine in an uncontrolled extension study with mean duration of follow-up of 2 years. No new safety signals were seen during this extended treatment with insulin glargine.

A crossover study comparing insulin glargine plus lispro insulin to NPH plus regular human insulin (each treatment administered for 16 weeks in random order) in 26 adolescent type 1 diabetic patients aged 12 to 18 years was also performed. As in the paediatric study described above, fasting plasma glucose reduction from baseline was greater in the insulin glargine group than in the NPH group. HbA1c changes from baseline were similar between treatment groups; however blood glucose values recorded overnight were significantly higher in the insulin glargine/ lispro group than the NPH/regular group, with a mean nadir of 5.4 mM vs. 4.1 mM. Correspondingly, the incidences of nocturnal hypoglycaemia were 32 % in the insulin glargine / lispro group vs. 52 % in the NPH / regular group.

A 24-week parallel group study was conducted in 125 children with type 1 diabetes mellitus aged 2 to 6 years, comparing insulin glargine given once daily in the morning to NPH insulin given once or twice daily as basal insulin. Both groups received bolus insulin before meals. The primary aim of demonstrating non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and there was a trend to an increase of hypoglycaemic events with insulin glargine [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)]. Glycohaemoglobin and glucose variabilities were comparable in both treatment groups. No new safety signals were observed in this trial.

**5.2 Pharmacokinetic properties**

**Absorption**

In healthy subjects and diabetic patients, insulin serum concentrations indicated a slower and much more prolonged absorption and showed a lack of a peak after subcutaneous injection of insulin glargine in comparison to human NPH insulin. Concentrations were thus consistent with the time profile of the pharmacodynamic activity of insulin glargine. Figure 1 above shows the activity profiles over time of insulin glargine and NPH insulin.

Insulin glargine injected once daily will reach steady state levels in 2-4 days after the first dose.

**Biotransformation**

After subcutaneous injection in diabetic patients, insulin glargine is rapidly metabolised at the carboxyl terminus of the Beta chain with formation of two active metabolites M1 (21A-Gly-insulin)
and M2 (21A-Gly-des-30B-Thr-insulin). In plasma, the principal circulating compound is the metabolite M1. The exposure to M1 increases with the administered dose of insulin glargine.

The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with insulin glargine is principally based on exposure to M1. Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable their concentration was independent of the administered dose of insulin glargine.

Elimination

When given intravenously the elimination half-life of insulin glargine and human insulin were comparable.

Special populations

In clinical studies, subgroup analyses based on age and gender did not indicate any difference in safety and efficacy in insulin glargine-treated patients compared to the entire study population.

Paediatric population

Pharmacokinetics in children aged 2 to less than 6 years with type 1 diabetes mellitus was assessed in one clinical study (see section 5.1). Plasma trough levels of insulin glargine and its main M1 and M2 metabolites were measured in children treated with insulin glargine, revealing plasma concentration patterns similar to adults, and providing no evidence for accumulation of insulin glargine or its metabolites with chronic dosing.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Zinc oxide
Metacresol
glycerol
hydrochloric acid (for pH adjustment)
sodium hydroxide (for pH adjustment)
water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

2 years.

Shelf life after first use

The medicinal product may be stored for a maximum of 28 days up to 30°C and away from direct heat or direct light. Pens in use must not be stored in the refrigerator. The pen cap must be put back on the pen after each injection in order to protect from light.
6.4 Special precautions for storage

Before use

Store in a refrigerator (2°C - 8°C).

Do not freeze.

Do not store ABASAGLAR next to the freezer compartment or a freezer pack.

Keep the cartridge in the outer carton in order to protect from light.

In use

For storage conditions after first opening of this medicinal product, see section 6.3.

6.5 Nature and contents of container

3 mL solution in a cartridge (type 1 colourless glass) with a plunger (chlorobutyl rubber) and a disc seal (laminate of polyisoprene and bromobutyl rubber) with aluminium seal.

Packs of 1, 2, 5, 10 and multipacks containing 10 (2 packs of 5) cartridges. Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

ABASAGLAR must not be mixed with any other insulin or medicinal products or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation.

Insulin pen

The ABASAGLAR cartridges are to be used only in conjunction with a reusable pen recommended for the use with Lilly insulin cartridges (see section 4.4).

The pen should be used as recommended in the information provided by the device manufacturer.

The manufacturer's instructions for using the pen must be followed carefully for loading the cartridge, attaching the needle, and administering the insulin injection.

If the insulin pen is damaged or not working properly (due to mechanical defects) it has to be discarded, and a new insulin pen has to be used.

If the pen malfunctions (see instructions for using the pen), the solution may be drawn from the cartridge into a syringe (suitable for an insulin with 100 units/mL) and injected.

It is important to ensure that syringes do not contain traces of any other material.

Cartridge

Inspect the cartridge before use. It must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of water-like consistency. Since ABASAGLAR is a solution, it does not require re-suspension before use. Air bubbles must be removed from the cartridge before injection (see instructions for using the pen).

To prevent the possible transmission of disease, each pen must be used by one patient only.
Empty cartridges must not be refilled and must be properly discarded. Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins (see section 4.4).

7.  MARKETING AUTHORISATION HOLDER

Eli Lilly Regional Operations GmbH., Kölblgas 8-10, 1030, Vienna, Austria.

8.  MARKETING AUTHORISATION NUMBER(S)

EU/1/14/944/001
EU/1/14/944/002
EU/1/14/944/003
EU/1/14/944/004
EU/1/14/944/009

9.  DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 9 September 2014

10.  DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
1. NAME OF THE MEDICINAL PRODUCT
ABASAGLAR 100 units/mL solution for injection in a pre-filled pen

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each mL contains 100 units insulin glargine* (equivalent to 3.64 mg).
Each pen contains 3 mL of solution for injection, equivalent to 300 units.
* Insulin glargine is produced by recombinant DNA technology in *Escherichia coli*.
For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM
Clear, colourless solution.

4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.

4.2 Posology and method of administration

Posology
ABASAGLAR contains insulin glargine, an insulin analogue and has a prolonged duration of action.
ABASAGLAR should be administered once daily at any time but at the same time each day.
The ABASAGLAR dose regimen (dose and timing) should be individually adjusted. In patients with
type 2 diabetes mellitus, ABASAGLAR can also be given together with orally active antidiabetic
medicinal products.
The potency of this medicinal product is stated in units. These units are exclusive to insulin glargine
and are not the same as IU or the units used to express the potency of other insulin analogues (see
section 5.1).

Special populations
Elderly population (≥65 years old)
In the elderly, progressive deterioration of renal function may lead to a steady decrease in insulin
requirements.
Renal impairment
In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.

Hepatic impairment
In patients with hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.

Paediatric population
Safety and efficacy of insulin glargine have been established in adolescents and children aged 2 years and older. Currently available data are described in sections 4.8, 5.1 and 5.2.

Safety and efficacy of insulin glargine have not been established in children below the age of 2 years. No data are available.

Transition from other insulins to ABASAGLAR
When changing from a treatment regimen with an intermediate or long-acting insulin to a regimen with ABASAGLAR, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast-acting insulin analogues or the dose of oral antidiabetic medicinal products).

To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with ABASAGLAR should reduce their daily dose of basal insulin by 20-30% during the first weeks of treatment.

During the first weeks the reduction should, at least partially, be compensated by an increase in mealtime insulin, after this period the regimen should be adjusted individually.

As with other insulin analogues, patients with high insulin doses because of antibodies to human insulin may experience an improved insulin response with ABASAGLAR.

Close metabolic monitoring is recommended during the transition and in the initial weeks thereafter. With improved metabolic control and resulting increase in insulin sensitivity a further adjustment in dose regimen may become necessary. Dose adjustment may also be required, for example, if the patient's weight or life-style changes, change of timing of insulin dose or other circumstances arise that increase susceptibility to hypoglycaemia or hyperglycaemia (see section 4.4).

Method of administration
ABASAGLAR is administered subcutaneously.

ABASAGLAR should not be administered intravenously. The prolonged duration of action of insulin glargine is dependent on its injection into subcutaneous tissue. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycaemia.

There are no clinically relevant differences in serum insulin or glucose levels after abdominal, deltoid or thigh administration of insulin glargine. Injection sites must be rotated within a given injection area from one injection to the next.

ABASAGLAR must not be mixed with any other insulin or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation.

For further details on handling, see section 6.6.

Before using ABASAGLAR KwikPen, the instructions for use included in the package leaflet must be read carefully (see section 6.6).
4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

ABASAGLAR is not the insulin of choice for the treatment of diabetic ketoacidosis. Instead, regular insulin administered intravenously is recommended in such cases.

In case of insufficient glucose control or a tendency to hyperglycaemic or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.

Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (regular, NPH, lente, long-acting, etc.), origin (animal, human, human insulin analogue) and/or method of manufacture may result in the need for a change in dose.

Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see section 4.8).

Hypoglycaemia

The time of occurrence of hypoglycaemia depends on the action profile of the insulins used and may, therefore, change when the treatment regimen is changed. Due to more sustained basal insulin supply with insulin glargine, less nocturnal but more early morning hypoglycaemia can be expected.

Particular caution should be exercised, and intensified blood glucose monitoring is advisable in patients in whom hypoglycaemic episodes might be of particular clinical relevance, such as in patients with significant stenoses of the coronary arteries or of the blood vessels supplying the brain (risk of cardiac or cerebral complications of hypoglycaemia) as well as in patients with proliferative retinopathy, particularly if not treated with photocoagulation (risk of transient amaurosis following hypoglycaemia).

Patients should be aware of circumstances where warning symptoms of hypoglycaemia are diminished. The warning symptoms of hypoglycaemia may be changed, be less pronounced or be absent in certain risk groups. These include patients:
- in whom glycaemic control is markedly improved,
- in whom hypoglycaemia develops gradually,
- who are elderly,
- after transfer from animal insulin to human insulin,
- in whom an autonomic neuropathy is present,
- with a long history of diabetes,
- suffering from a psychiatric illness,
- receiving concurrent treatment with certain other medicinal products (see section 4.5).

Such situations may result in severe hypoglycaemia (and possibly loss of consciousness) prior to the patient's awareness of hypoglycaemia.

The prolonged effect of subcutaneous insulin glargine may delay recovery from hypoglycaemia.

If normal or decreased values for glycated haemoglobin are noted, the possibility of recurrent, unrecognised (especially nocturnal) episodes of hypoglycaemia must be considered.

Adherence of the patient to the dose and dietary regimen, correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia. Factors increasing the
susceptibility to hypoglycaemia require particularly close monitoring and may necessitate dose adjustment. These include:
- change in the injection area,
- improved insulin sensitivity (e.g., by removal of stress factors),
- unaccustomed, increased or prolonged physical activity,
- intercurrent illness (e.g. vomiting, diarrhoea),
- inadequate food intake,
- missed meals,
- alcohol consumption,
- certain uncompensated endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or adrenocortical insufficiency),
- concomitant treatment with certain other medicinal products.

**Intercurrent illness**

Intercurrent illness requires intensified metabolic monitoring. In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin requirement is often increased. Patients with type 1 diabetes must continue to consume at least a small amount of carbohydrates on a regular basis, even if they are able to eat only little or no food, or are vomiting etc. and they must never omit insulin entirely.

**Medication errors**

Medication errors have been reported in which other insulins, particularly short-acting insulins, have been accidentally administered instead of insulin glargine. Insulin label must always be checked before each injection to avoid medication errors between ABASAGLAR and other insulins.

**Combination of ABASAGLAR with pioglitazone**

Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and ABASAGLAR is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.

**Excipients**

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e., essentially “sodium-free”.

4.5 **Interaction with other medicinal products and other forms of interaction**

A number of substances affect glucose metabolism and may require dose adjustment of insulin glargine.

Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates, somatostatin analogues and sulphonamide antibiotics.

Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens, progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors.
Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood-glucose lowering effect of insulin. Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia.

In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine and reserpine, the signs of adrenergic counter-regulation may be reduced or absent.

4.6 Fertility, pregnancy and lactation

Pregnancy

For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available. A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine.

Animal data do not indicate reproductive toxicity.

The use of ABASAGLAR may be considered during pregnancy, if necessary.

It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy to prevent adverse outcomes associated with hyperglycaemia. Insulin requirements may decrease during the first trimester and generally increase during the second and third trimesters. Immediately after delivery, insulin requirements decline rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose control is essential.

Breast-feeding

It is unknown whether insulin glargine is excreted in human milk. No metabolic effects of ingested insulin glargine on the breastfed newborn/infant are anticipated since insulin glargine as a peptide is digested into amino acids in the human gastrointestinal tract.

Breast-feeding women may require adjustments in insulin dose and diet.

Fertility

Animal studies do not indicate direct harmful effects with respect to fertility.

4.7 Effects on ability to drive and use machines

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machines).

Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. This is particularly important in those who have reduced or absent awareness of the warning symptoms of hypoglycaemia or have frequent episodes of hypoglycaemia. It should be considered whether it is advisable to drive or operate machines in these circumstances.

4.8 Undesirable effects

Summary of safety profile

Hypoglycaemia, in general the most frequent adverse reaction of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement.
Tabulated list of adverse reactions

The following related adverse reactions from clinical trials are listed below as MedDRA preferred term by system organ class and in order of decreasing incidence (very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1,000; very rare: <1/10,000).

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

<table>
<thead>
<tr>
<th>MedDRA system organ classes</th>
<th>Very common</th>
<th>Common</th>
<th>Uncommon</th>
<th>Rare</th>
<th>Very rare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune system disorders</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Allergic reactions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypoglycaemia</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysgeusia</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Eyes disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visual impairment</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Retinopathy</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipohypertrophy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Lipoatrophy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myalgia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injection site reactions</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Oedema</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

Description of selected adverse reactions

**Metabolism and nutrition disorders**
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage. Prolonged or severe hypoglycaemic episodes may be life-threatening. In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter-regulation. Generally, the greater and more rapid the decline in blood glucose, the more marked is the phenomenon of counter-regulation and its symptoms.

**Immune system disorders**
Immediate-type allergic reactions to insulin are rare. Such reactions to insulin (including insulin glargine) or the excipients may, for example, be associated with generalised skin reactions, angio-oedema, bronchospasm, hypotension and shock, and may be life-threatening.

Insulin administration may cause insulin antibodies to form. In clinical studies, antibodies that cross-react with human insulin and insulin glargine were observed with the same frequency in both NPH-insulin and insulin glargine treatment groups. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia.

**Eyes disorders**
A marked change in glycaemic control may cause temporary visual impairment, due to temporary alteration in the turgidity and refractive index of the lens.
Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy. However, intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy. In patients with proliferative retinopathy, particularly if not treated with photocoagulation, severe hypoglycaemic episodes may result in transient amaurosis.

**Skin and subcutaneous tissue disorders**

As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions.

**General disorders and administration site conditions**

Injection site reactions include redness, pain, itching, hives, swelling, or inflammation. Most minor reactions to insulins at the injection site usually resolve in a few days to a few weeks.

Rarely, insulin may cause sodium retention and oedema particularly if previously poor metabolic control is improved by intensified insulin therapy.

**Paediatric population**

In general, the safety profile for children and adolescents (≤ 18 years of age) is similar to the safety profile for adults. The adverse reaction reports received from post marketing surveillance included relatively more frequent injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) in children and adolescents (≤ 18 years of age) than in adults. Clinical study safety data are not available for children under 2 years.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

### 4.9 Overdose

**Symptoms**

Insulin overdose may lead to severe and sometimes long-term and life-threatening hypoglycaemia.

**Management**

Mild episodes of hypoglycaemia can usually be treated with oral carbohydrates. Adjustments in dose of the medicinal product, meal patterns, or physical activity may be needed.

More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.

### 5. PHARMACOLOGICAL PROPERTIES

#### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs used in diabetes, insulins and analogues for injection, long-acting. ATC Code: A10AE04.

**Mechanism of action**

Insulin glargine is a human insulin analogue designed to have a low solubility at neutral pH. It is completely soluble at the acidic pH of the ABASAGLAR injection solution (pH 4). After injection into the subcutaneous tissue, the acidic solution is neutralised leading to formation of micro-precipitates from which small amounts of insulin glargine are continuously released, providing a smooth, peakless, predictable concentration/time profile with a prolonged duration of action.

Insulin glargine is metabolised into 2 active metabolites M1 and M2 (see section 5.2).

*Insulin receptor binding*

*In vitro* studies indicate that the affinity of insulin glargine and its metabolites M1 and M2 for the human insulin receptor is similar to the one of human insulin.

IGF-1 receptor binding: The affinity of insulin glargine for the human IGF-1 receptor is approximately 5 to 8-fold greater than that of human insulin (but approximately 70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1 receptor with slightly lower affinity compared to human insulin.

The total therapeutic insulin concentration (insulin glargine and its metabolites) found in type 1 diabetic patients was markedly lower than what would be required for a half maximal occupation of the IGF-1 receptor and the subsequent activation of the mitogenic-proliferative pathway initiated by the IGF-1 receptor. Physiological concentrations of endogenous IGF-1 may activate the mitogenic-proliferative pathway; however, the therapeutic concentrations found in insulin therapy, including in ABASAGLAR therapy, are considerably lower than the pharmacological concentrations required to activate the IGF-1 pathway.

**Pharmacodynamic effects**

The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis and enhances protein synthesis.

In clinical pharmacology studies, intravenous insulin glargine and human insulin have been shown to be equipotent when given at the same doses. As with all insulins, the time course of action of insulin glargine may be affected by physical activity and other variables.

In euglycaemic clamp studies in healthy subjects or in patients with type 1 diabetes, the onset of action of subcutaneous insulin glargine was slower than with human NPH insulin, its effect profile was smooth and peakless, and the duration of its effect was prolonged.

The following graph shows the results from a study in patients:
The longer duration of action of subcutaneous insulin glargine is directly related to its slower rate of absorption and supports once daily administration. The time course of action of insulin and insulin analogues such as insulin glargine may vary considerably in different individuals or within the same individual.

In a clinical study, symptoms of hypoglycaemia or counter-regulatory hormone responses were similar after intravenous insulin glargine and human insulin both in healthy volunteers and patients with type 1 diabetes.

Clinical safety and efficacy

Effects of insulin glargine (once daily) on diabetic retinopathy were evaluated in an open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2 diabetic patients in which progression of retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by fundus photography. No significant difference was seen in the progression of diabetic retinopathy when insulin glargine was compared to NPH insulin.

The ORIGIN (Outcome Reduction with Initial Glargine INtervention) study was a multicenter, randomized, 2x2 factorial design study conducted in 12,537 participants at high cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus treated with ≤1 antidiabetic oral agent (88% of participants). Participants were randomized (1:1) to receive insulin glargine (n=6264), titrated to reach FPG ≤95 mg/dL (5.3 mM), or standard care (n=6273).

The first co-primary efficacy outcome was the time to the first occurrence of CV death, nonfatal myocardial infarction (MI), or nonfatal stroke, and the second co-primary efficacy outcome was the time to the first occurrence of any of the first co-primary events, or revascularisation procedure (coronary, carotid, or peripheral), or hospitalisation for heart failure.

Secondary endpoints included all-cause mortality and a composite microvascular outcome.

Insulin glargine did not alter the relative risk for CV disease and CV mortality when compared to standard of care. There were no differences between insulin glargine and standard care for the two co-primary outcomes; for any component endpoint comprising these outcomes; for all-cause mortality; or for the composite microvascular outcome.
Mean dose of insulin glargine by study end was 0.42 U/kg. At baseline, participants had a median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9 to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care group throughout the duration of follow-up. The rates of severe hypoglycaemia (affected participants per 100 participant years of exposure) were 1.05 for insulin glargine and 0.30 for standard care group and the rates of confirmed non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard care group. Over the course of this 6-year study, 42% of the insulin glargine group did not experience any hypoglycaemia.

At the last on-treatment visit, there was a mean increase in body weight from baseline of 1.4 kg in the insulin glargine group and a mean decrease of 0.8 kg in the standard care group.

Paediatric population

In a randomised, controlled clinical study, paediatric patients (age range 6 to 15 years) with type 1 diabetes (n=349) were treated for 28 weeks with a basal-bolus insulin regimen where regular human insulin was used before each meal. Insulin glargine was administered once daily at bedtime and NPH human insulin was administered once or twice daily. Similar effects on glycohaemoglobin and the incidence of symptomatic hypoglycaemia were observed in both treatment groups, however fasting plasma glucose decreased more from baseline in the insulin glargine group than in the NPH group. There was less severe hypoglycaemia in the insulin glargine group as well. One hundred forty three of the patients treated with insulin glargine in this study continued treatment with insulin glargine in an uncontrolled extension study with mean duration of follow-up of 2 years. No new safety signals were seen during this extended treatment with insulin glargine.

A crossover study comparing insulin glargine plus lispro insulin to NPH plus regular human insulin (each treatment administered for 16 weeks in random order) in 26 adolescent type 1 diabetic patients aged 12 to 18 years was also performed. As in the paediatric study described above, fasting plasma glucose reduction from baseline was greater in the insulin glargine group than in the NPH group. HbA1c changes from baseline were similar between treatment groups; however blood glucose values recorded overnight were significantly higher in the insulin glargine/ lispro group than the NPH/regular group, with a mean nadir of 5.4 mM vs. 4.1 mM. Correspondingly, the incidences of nocturnal hypoglycaemia were 32 % in the insulin glargine / lispro group vs. 52 % in the NPH / regular group.

A 24-week parallel group study was conducted in 125 children with type 1 diabetes mellitus aged 2 to 6 years, comparing insulin glargine given once daily in the morning to NPH insulin given once or twice daily as basal insulin. Both groups received bolus insulin before meals. The primary aim of demonstrating non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and there was a trend to an increase of hypoglycaemic events with insulin glargine [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)]. Glycohaemoglobin and glucose variabilities were comparable in both treatment groups. No new safety signals were observed in this trial.

5.2 Pharmacokinetic properties

Absorption

In healthy subjects and diabetic patients, insulin serum concentrations indicated a slower and much more prolonged absorption and showed a lack of a peak after subcutaneous injection of insulin glargine in comparison to human NPH insulin. Concentrations were thus consistent with the time profile of the pharmacodynamic activity of insulin glargine. Figure 1 above shows the activity profiles over time of insulin glargine and NPH insulin.

Insulin glargine injected once daily will reach steady state levels in 2-4 days after the first dose.

Biotransformation

After subcutaneous injection in diabetic patients, insulin glargine is rapidly metabolised at the carboxyl terminus of the Beta chain with formation of two active metabolites M1 (21A-Gly-insulin)
and M2 (21A-Gly-des-30B-Thr-insulin). In plasma, the principal circulating compound is the metabolite M1. The exposure to M1 increases with the administered dose of insulin glargine.

The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with insulin glargine is principally based on exposure to M1. Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable their concentration was independent of the administered dose of insulin glargine.

Elimination

When given intravenously the elimination half-life of insulin glargine and human insulin were comparable.

Special populations

In clinical studies, subgroup analyses based on age and gender did not indicate any difference in safety and efficacy in insulin glargine-treated patients compared to the entire study population.

Paediatric population

Pharmacokinetics in children aged 2 to less than 6 years with type 1 diabetes mellitus was assessed in one clinical study (see section 5.1). Plasma trough levels of insulin glargine and its main M1 and M2 metabolites were measured in children treated with insulin glargine, revealing plasma concentration patterns similar to adults, and providing no evidence for accumulation of insulin glargine or its metabolites with chronic dosing.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Zinc oxide
Metacresol
glycerol
hydrochloric acid (for pH adjustment)
sodium hydroxide (for pH adjustment)
water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

2 years.

Shelf life after first use

The medicinal product may be stored for a maximum of 28 days up to 30°C and away from direct heat or direct light. Pens in use must not be stored in the refrigerator. The pen cap must be put back on the pen after each injection in order to protect from light.
6.4 Special precautions for storage

Before use

Store in a refrigerator (2°C - 8°C).

Do not freeze.

Do not store ABASAGLAR next to the freezer compartment or a freezer pack.

Keep the pre-filled pen in the outer carton in order to protect from light.

In use

For storage conditions after first opening of this medicinal product, see section 6.3.

6.5 Nature and contents of container

3 mL solution in a cartridge (type 1 colourless glass) with a plunger (chlorobutyl rubber) and a disc seal (laminate of polyisoprene and bromobutyl rubber) with aluminium seal.

The cartridge is sealed in a disposable pen injector.

Packs of 1, 2, 5 and multipacks containing 10 (2 packs of 5) pens. Not all pack sizes may be marketed.

Needles are not included in the pack.

6.6 Special precautions for disposal and other handling

ABASAGLAR must not be mixed with any other insulin or medicinal products or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation.

ABASAGLAR KwikPen

Inspect the cartridge before use. It must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of water-like consistency. Since ABASAGLAR is a solution, it does not require re-suspension before use.

ABASAGLAR must not be mixed with any other insulin or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation.

Empty pens must never be reused and must be properly discarded.

To prevent the possible transmission of disease, each pen must be used by one patient only.

Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins (see section 4.4).

Handling of the pen

The patient should be advised to read the instructions for use included in the package leaflet carefully before using ABASAGLAR KwikPen.
7. MARKETING AUTHORISATION HOLDER

Eli Lilly Regional Operations GmbH., Köbllgasse 8-10, 1030, Vienna, Austria.

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/14/944/005
EU/1/14/944/006
EU/1/14/944/007
EU/1/14/944/008
EU/1/14/944/010
EU/1/14/944/011
EU/1/14/944/012
EU/1/14/944/013

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 9 September 2014

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency [http://www.ema.europa.eu](http://www.ema.europa.eu)
ANNEX II

A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturers of the biological active substance

Lilly del Caribe, Inc.
12.3 km 65th Infantry Road
Carolina, PR 00985
Puerto Rico

Eli Lilly and Company
Indianapolis
Indiana 46285
USA

Name and address of the manufacturer responsible for batch release

Lilly France S.A.S.
2, rue du Colonel Lilly
F-67640 Fegersheim
France

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

• Periodic safety update reports

The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

• Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

• At the request of the European Medicines Agency;
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
## PARTICULARS TO APPEAR ON THE OUTER PACKAGING

**OUTER CARTON – Cartridge. Pack of 1, 2, 5 and 10**

### 1. NAME OF THE MEDICINAL PRODUCT

ABASAGLAR 100 units/mL solution for injection in a cartridge

Insulin glargine

### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each mL contains 100 units insulin glargine (equivalent to 3.64 mg).

### 3. LIST OF EXCIPIENTS

Excipients: zinc oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide (for pH adjustment), water for injections

### 4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection

- 1 cartridge of 3 mL.
- 2 cartridges of 3 mL.
- 5 cartridges of 3 mL.
- 10 cartridges of 3 mL.

### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

These cartridges are for use with a 3 mL pen only.

Read the package leaflet before use.

Subcutaneous use.

### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

### 7. OTHER SPECIAL WARNING(S), IF NECESSARY
8. EXPERY DATE

EXP

Discard 28 days after first use.

9. SPECIAL STORAGE CONDITIONS

Before use:

Store in a refrigerator.
Do not freeze.
Store in original package to protect from light.

In use:

Store below 30 º C.
Do not refrigerate or freeze.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Regional Operations GmbH.,
Köbllgasse 8-10,
1030, Vienna,
Austria.

12. MARKETING AUTHORISATION NUMBER(S)

- EU/1/14/944/001 1 cartridge
- EU/1/14/944/002 2 cartridges
- EU/1/14/944/003 5 cartridges
- EU/1/14/944/009 10 cartridges

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE
ABASAGLAR
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
INTERMEDIATE CARTON (without blue box) component of multipack- Cartridge

1. NAME OF THE MEDICINAL PRODUCT

ABASAGLAR 100 units/mL solution for injection in a cartridge
Insulin glargine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each mL contains 100 units insulin glargine (equivalent to 3.64 mg).

3. LIST OF EXCIPIENTS

Excipients: zinc oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide (for pH adjustment), water for injections

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection
Multipack: 5 cartridges of 3 mL. Component of a multipack, can’t be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

These cartridges are for use with a 3 mL pen only.
Read the package leaflet before use.
Subcutaneous use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
Discard 28 days after first use.
9. SPECIAL STORAGE CONDITIONS

Before use:

Store in a refrigerator.
Do not freeze.
Store in original package to protect from light.

In use:

Store below 30 °C.
Do not refrigerate or freeze.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Regional Operations GmbH.,
Kölblgasse 8-10,
1030, Vienna,
Austria.

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/14/944/004

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

ABASAGLAR
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON (with blue box) multipack- Cartridge

1. NAME OF THE MEDICINAL PRODUCT

ABASAGLAR 100 units/mL solution for injection in a cartridge
Insulin glargine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each mL contains 100 units insulin glargine (equivalent to 3.64 mg).

3. LIST OF EXCIPIENTS

Excipients: zinc oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide (for pH adjustment), water for injections

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection

Multipack: 10 (2 packs of 5) cartridges of 3 mL.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

These cartridges are for use with a 3 mL pen only.

Read the package leaflet before use.

Subcutaneous use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

Discard 28 days after first use.
9. SPECIAL STORAGE CONDITIONS

Before use:

Store in a refrigerator.
Do not freeze.
Store in original package to protect from light.

In use:

Store below 30 ° C.
Do not refrigerate or freeze.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Regional Operations GmbH.,
Köblbgasse 8-10,
1030, Vienna,
Austria.

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/14/944/004

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

ABASAGLAR
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON – KwikPen. Pack of 1, 2 and 5

1. NAME OF THE MEDICINAL PRODUCT

ABASAGLAR 100 units/mL solution for injection in a pre-filled pen
Insulin glargine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each mL contains 100 units insulin glargine (equivalent to 3.64 mg).

3. LIST OF EXCIPIENTS

Excipients: zinc oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide (for pH adjustment), water for injections

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection. KwikPen

1 pen of 3 mL.
2 pens of 3 mL.
5 pens of 3 mL.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Subcutaneous use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

NOW DIALS UP TO 80 units

8. EXPIRY DATE

EXP
Discard pen 28 days after first use.
9. SPECIAL STORAGE CONDITIONS

Before use:

Store in a refrigerator.
Do not freeze.
Store in original package to protect from light.

In use:

Store below 30 °C.
Do not refrigerate or freeze.
Recap the pen after use to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Regional Operations GmbH,
Köbligasse 8-10,
1030, Vienna,
Austria.

12. MARKETING AUTHORISATION NUMBER(S)

<table>
<thead>
<tr>
<th>Number</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/14/944/005</td>
<td>1 pen</td>
</tr>
<tr>
<td>EU/1/14/944/006</td>
<td>2 pens</td>
</tr>
<tr>
<td>EU/1/14/944/007</td>
<td>5 pens</td>
</tr>
<tr>
<td>EU/1/14/944/010</td>
<td>1 pen</td>
</tr>
<tr>
<td>EU/1/14/944/011</td>
<td>2 pens</td>
</tr>
<tr>
<td>EU/1/14/944/012</td>
<td>5 pens</td>
</tr>
</tbody>
</table>

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

ABASAGLAR
1. NAME OF THE MEDICINAL PRODUCT

ABASAGLAR 100 units/mL solution for injection in a pre-filled pen

Insulin glargine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each mL contains 100 units insulin glargine (equivalent to 3.64 mg).

3. LIST OF EXCIPIENTS

Excipients: zinc oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide (for pH adjustment), water for injections

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection. KwikPen

Multipack: 5 pens of 3 mL. Component of a multipack, can’t be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Subcutaneous use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

NOW DIALS UP TO 80 units

8. EXPIRY DATE

EXP

Discard pen 28 days after first use.
9. SPECIAL STORAGE CONDITIONS

Before use:

Store in a refrigerator.
Do not freeze.
Store in original package to protect from light.

In use:

Store below 30 °C.
Do not refrigerate or freeze.
Recap the pen after use to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Regional Operations GmbH,
Köbltgasse 8-10,
1030, Vienna,
Austria.

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/14/944/008
EU/1/14/944/013

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

ABASAGLAR
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON (with blue box) multipack – KwikPen

1. **NAME OF THE MEDICINAL PRODUCT**

ABASAGLAR 100 units/mL solution for injection in a pre-filled pen

Insulin glargine

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

Each mL contains 100 units insulin glargine (equivalent to 3.64 mg).

3. **LIST OF EXCIPIENTS**

Excipients: zinc oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide (for pH adjustment), water for injections

4. **PHARMACEUTICAL FORM AND CONTENTS**

Solution for injection. KwikPen

Multipack: 10 (2 packs of 5) pens of 3 mL.

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Subcutaneous use.

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

**NOW DIALS UP TO 80 units**

8. **EXPIRY DATE**

EXP

Discard pen 28 days after first use.
9. SPECIAL STORAGE CONDITIONS

Before use:

Store in a refrigerator.
Do not freeze.
Store in original package to protect from light.

In use:

Store below 30 º C.
Do not refrigerate or freeze.
Recap the pen after use to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Regional Operations GmbH.,
Köbligasse 8-10,
1030, Vienna,
Austria.

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/14/944/008
EU/1/14/944/013

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

ABASAGLAR
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
CARTRIDGE LABEL

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

ABASAGLAR 100 U/mL, injection
Insulin glargine
SC use

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

3 mL

6. OTHER
### MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

LABEL TEXT – KwikPen

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABASAGLAR 100 U/mL injection</td>
</tr>
<tr>
<td>KwikPen</td>
</tr>
<tr>
<td>Insulin glargine</td>
</tr>
<tr>
<td>SC use</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. METHOD OF ADMINISTRATION</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 mL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. OTHER</th>
</tr>
</thead>
</table>
Package leaflet: Information for the user

ABASAGLAR 100 units/mL solution for injection in a cartridge
Insulin glargine

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you. The instructions for using the insulin pen are provided with your insulin pen. Refer to them before using your medicine.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is this leaflet about

1. What ABASAGLAR is and what it is used for
2. What you need to know before you use ABASAGLAR
3. How to use ABASAGLAR
4. Possible side effects
5. How to store ABASAGLAR
6. Contents of the pack and other information

1. What ABASAGLAR is and what it is used for

ABASAGLAR is a solution for injection containing insulin glargine. Insulin glargine is a modified insulin, very similar to human insulin.

ABASAGLAR is used to treat diabetes mellitus in adults, adolescents and children aged 2 years and above.

Diabetes mellitus is a disease where your body does not produce enough insulin to control the level of blood sugar. Insulin glargine has a long and steady blood-sugar-lowering action.

2. What you need to know before you use ABASAGLAR

Do not use ABASAGLAR

If you are allergic to insulin glargine or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist or nurse before using ABASAGLAR. Follow closely the instructions for posology, monitoring (blood and urine tests), diet and physical activity (physical work and exercise) as discussed with your doctor.

If your blood sugar is too low (hypoglycaemia), follow the guidance for hypoglycaemia (see box at the end of this leaflet).
Travel
Before travelling consult your doctor. You may need to talk about:
- the availability of your insulin in the country you are visiting,
- supplies of insulin, syringes etc.,
- correct storage of your insulin while travelling,
- timing of meals and insulin administration while travelling,
- the possible effects of changing to different time zones,
- possible new health risks in the countries to be visited,
- what you should do in emergency situations when you feel unwell or become ill.

Illnesses and injuries
In the following situations, the management of your diabetes may require a lot of care (for example, adjustment to insulin dose, blood and urine tests):
- If you are ill or have a major injury then your blood sugar level may increase (hyperglycaemia).
- If you are not eating enough your blood sugar level may become too low (hypoglycaemia).
In most cases you will need a doctor. **Make sure that you contact a doctor early.**

If you have type 1 diabetes (insulin dependent diabetes mellitus), do not stop your insulin and continue to get enough carbohydrates. Always tell people who are caring for you or treating you that you require insulin.

Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).

Other medicines and ABASAGLAR
Some medicines cause changes in the blood sugar level (decrease, increase or both depending on the situation). In each case, it may be necessary to adjust your insulin dose to avoid blood sugar levels that are either too low or too high. Be careful when you start or stop taking another medicine.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Before taking a medicine ask your doctor if it can affect your blood sugar level and what action, if any, you need to take.

**Medicines that may cause your blood sugar level to fall (hypoglycaemia) include:**
- all other medicines to treat diabetes,
- angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure),
- disopyramide (used to treat certain heart conditions),
- fluoxetine (used to treat depression),
- fibrates (used to lower high levels of blood lipids),
- monoamine oxidase (MAO) inhibitors (used to treat depression),
- pentoxifylline, propoxyphene, salicylates (such as aspirin, used to relieve pain and lower fever),
- somatostatin analogues (such as octreotide, used to treat an uncommon condition in which you make too much growth hormone),
- sulphonamide antibiotics.

**Medicines that may cause your blood sugar level to rise (hyperglycaemia) include:**
- corticosteroids (such as "cortisone" used to treat inflammation),
- danazol (medicine acting on ovulation),
- diazoxide (used to treat high blood pressure),
- diuretics (used to treat high blood pressure or excessive fluid retention),
- glucagon (pancreas hormone used to treat severe hypoglycaemia),
- isoniazid (used to treat tuberculosis),
- oestrogens and progestogens (such as in the contraceptive pill used for birth control),
- phenothiazine derivatives (used to treat psychiatric disorders),
- somatropin (growth hormone),
- sympathomimetic medicines (such as epinephrine [adrenaline], salbutamol, terbutaline used to treat asthma),
- thyroid hormones (used to treat thyroid gland disorders),
- atypical antipsychotic medicines (such as clozapine, olanzapine),
- protease inhibitors (used to treat HIV).

Your blood sugar level may either rise or fall if you take:

- beta-blockers (used to treat high blood pressure),
- clonidine (used to treat high blood pressure),
- lithium salts (used to treat psychiatric disorders).

Pentamidine (used to treat some infections caused by parasites) may cause hypoglycaemia which may sometimes be followed by hyperglycaemia.

Beta-blockers like other sympatholytic medicines (such as clonidine, guanethidine, and reserpine) may weaken or suppress entirely the first warning symptoms which help you to recognise a hypoglycaemia. If you are not sure whether you are taking one of those medicines ask your doctor or pharmacist.

**ABASAGLAR with alcohol**

Your blood sugar levels may either rise or fall if you drink alcohol.

**Pregnancy and breast-feeding**

Ask your doctor or pharmacist for advice before taking any medicine. Inform your doctor if you are planning to become pregnant, or if you are already pregnant. Your insulin dose may need to be changed during pregnancy and after giving birth. Particularly careful control of your diabetes, and prevention of hypoglycaemia, is important for the health of your baby. If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet.

**Driving and using machines**

Your ability to concentrate or react may be reduced if:
- you have hypoglycaemia (low blood sugar levels),
- you have hyperglycaemia (high blood sugar levels),
- you have problems with your sight.

Keep this possible problem in mind in all situations where you might put yourself and others at risk (such as driving a car or operating machines). You should contact your doctor for advice on driving if:
- you have frequent episodes of hypoglycaemia,
- the first warning symptoms which help you to recognise hypoglycaemia are reduced or absent.

**Important information about some of the ingredients of ABASAGLAR**

This medicine contains less than 1 mmol (23 mg) sodium per dose, which means it is essentially ‘sodium-free’.

**3. How to use ABASAGLAR**

Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Dose

Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will:

- determine how much ABASAGLAR per day you will need and at what time,
- tell you when to check your blood sugar level, and whether you need to carry out urine tests,
- tell you when you may need to inject a higher or lower dose of ABASAGLAR.

ABASAGLAR is a long-acting insulin. Your doctor may tell you to use it in combination with a short-acting insulin or with tablets used to treat high blood sugar levels.

Many factors may influence your blood sugar level. You should know these factors so that you are able to react correctly to changes in your blood sugar level and to prevent it from becoming too high or too low. See the box at the end of this leaflet for further information.

Use in children and adolescents

ABASAGLAR can be used in adolescents and children aged 2 years and above. There is no experience with the use of ABASAGLAR in children below the age of 2 years.

Frequency of administration

You need one injection of ABASAGLAR every day, at the same time of the day.

Method of administration

ABASAGLAR is injected under the skin. Do NOT inject ABASAGLAR in a vein, since this will change its action and may cause hypoglycaemia.

Your doctor will show you in which area of the skin you should inject ABASAGLAR. With each injection, change the puncture site within the particular area of skin that you are using.

How to handle the cartridges

The ABASAGLAR cartridges are to be used only in pens recommended for Lilly insulin cartridges to ensure you get the correct dose. Not all of these pens may be marketed in your country.

The pen should be used as recommended in the information provided by the device manufacturer.

The manufacturer’s instructions for using the pen must be followed carefully for loading the cartridge, attaching the needle, and administering the insulin injection.

To prevent the possible transmission of disease, each pen must be used by one patient only.

Look at the cartridge before you use it. Only use it if the solution is clear, colourless and water-like, and has no visible particles in it. Do not shake or mix it before use.

Always use a new cartridge if you notice that your blood sugar control is unexpectedly getting worse. This is because the insulin may have lost some of its effectiveness. If you think you may have a problem with ABASAGLAR, have it checked by your doctor or pharmacist.

Special care before injection

Before injection remove any air bubbles (see instructions for using the pen).
Make sure that neither alcohol nor other disinfectants or other substances contaminate the insulin.

Do not re-fill and re-use empty cartridges. Do not add any other insulin to the cartridge. Do not mix ABASAGLAR with any other insulins or medicines. Do not dilute it. Mixing or diluting may change the action of ABASAGLAR.

**Problems with the insulin pen?**

Refer to the manufacturer’s instructions for using the pen.

**If the insulin pen is damaged or not working properly (due to mechanical defects) it has to be discarded, and a new insulin pen has to be used.**

If the insulin pen does not function well, you can draw the insulin from the cartridge into a syringe for injection. Therefore, keep injection syringes and needles as well. However, use only injection syringes which are designed for an insulin concentration of 100 units per millilitre.

**If you use more ABASAGLAR than you should**

- If you have injected too much ABASAGLAR, your blood sugar level may become too low (hypoglycaemia). Check your blood sugar frequently. In general, to prevent hypoglycaemia you must eat more food and monitor your blood sugar. For information on the treatment of hypoglycaemia, see box at the end of this leaflet.

**If you forget to use ABASAGLAR**

- If you have missed a dose of ABASAGLAR or if you have not injected enough insulin, your blood sugar level may become too high (hyperglycaemia). Check your blood sugar frequently. For information on the treatment of hyperglycaemia, see box at the end of this leaflet.

- Do not take a double dose to make up for a forgotten dose.

**If you stop using ABASAGLAR**

This could lead to severe hyperglycaemia (very high blood sugar) and ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar). Do not stop ABASAGLAR without speaking to a doctor, who will tell you what needs to be done.

**Insulin Mix-ups**

You must always check the insulin label before each injection to avoid mix-ups between ABASAGLAR and other insulins.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Hypoglycaemia (low blood sugar) can be very serious.** If your blood sugar level falls too much you may become unconscious. Serious hypoglycaemia may cause brain damage and may be life-threatening. If you have symptoms of low blood sugar, take actions to increase your blood sugar level immediately.

**If you experience the following symptoms, contact your doctor immediately:** large-scale skin reactions (rash and itching all over the body), severe swelling of skin or mucous membranes (angiooedema), shortness of breath, a fall in blood pressure with rapid heartbeat and sweating. These could be symptoms of severe allergic reactions to insulins and may become life threatening.
Very common side effects (may affect more than 1 in 10 people)

- **Hypoglycaemia**

As with all insulin therapy, the most frequent side effect is hypoglycaemia.

Hypoglycaemia (low blood sugar) means that there is not enough sugar in the blood. For further information on the side effects of low blood sugar or high blood sugar, see the box at the end of this leaflet.

Common side effects (may affect up to 1 in 10 people)

- **Skin changes at the injection site**

If you inject your insulin too often at the same skin site, fatty tissue under the skin at this site may either shrink (lipoatrophy) or thicken (lipohypertrophy). Thickening of fatty tissue may occur in 1 to 2 % of patients while shrinking may occur uncommonly. Insulin that you inject in such a site may not work very well. Changing the injection site with each injection may help to prevent such skin changes.

- **Skin and allergic reactions**

3 to 4 % of patients may experience reactions at the injection site (such as reddening, unusually intense pain on injection, itching, hives, swelling or inflammation). They can also spread around the injection site. Most minor reactions to insulins usually resolve in a few days to a few weeks.

Rare side effects (may affect up to 1 in 1,000 people)

Severe allergic reactions to insulins

Associated symptoms may include large-scale skin reactions (rash and itching all over the body), severe swelling of skin or mucous membranes (angioedema), shortness of breath, a fall in blood pressure with rapid heartbeat and sweating. These could be symptoms of severe allergic reactions to insulins and may become life-threatening.

Eye reactions

A marked change (improvement or worsening) in your blood sugar control can disturb your vision temporarily. If you have proliferative retinopathy (an eye disease related to diabetes) severe hypoglycaemic attacks may cause temporary loss of vision.

General disorders

In rare cases, insulin treatment may also cause temporary build-up of water in the body, with swelling in the calves and ankles.

Very rare side-effects (may affect up to 1 in 10,000 people)

In very rare cases, dysgeusia (taste disorders) and myalgia (muscular pain) can occur.

Other side effects with frequency not known (frequency cannot be estimated from available data)

Insulin treatment can cause the body to produce antibodies to insulin (substances that act against insulin). Rarely, this may require a change to your insulin dose.

Use in children and adolescents

In general, the side effects in children and adolescents of 18 years of age or less are similar to those seen in adults.
Complaints of injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) are reported relatively more frequently in children and adolescents of 18 years of age or less than in adults.

Clinical study safety data are not available for children under 2 years.

**Reporting of side effects**

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store ABASAGLAR**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the label of the cartridge after “EXP”. The expiry date refers to the last day of that month.

**Unopened cartridges**

Store in a refrigerator (2°C - 8°C). Do not freeze.

Do not put ABASAGLAR next to the freezer compartment or a freezer pack.

Keep the cartridge in the outer carton in order to protect from light.

**In-use cartridges**

Cartridges in use (in the insulin pen) or carried as a spare may be stored for a maximum of 28 days up to 30°C and away from direct heat or direct light. The cartridge in use must not be stored in a refrigerator. Do not use it after this time period.

Do not use ABASAGLAR if you notice particles in it. Only use ABASAGLAR if the solution is clear, colourless and water like.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What ABASAGLAR contains**

- The active substance is insulin glargine. Each millilitre of the solution contains 100 units of the active substance insulin glargine (equivalent to 3.64 mg).
- The other ingredients are: zinc oxide, metacresol, glycerol, sodium hydroxide (see section 2 “Important information about some of the ingredients of ABASAGLAR”), hydrochloric acid and water for injections.

**What ABASAGLAR looks like and contents of the pack**

ABASAGLAR 100 units/mL solution for injection in a cartridge is a clear and colourless solution.

ABASAGLAR comes in a special cartridge to be used only in pens recommended for Lilly insulin cartridges. Each cartridge contains 3 mL of solution for injection (equivalent to 300 units) and they are available in packs of 1, 2, 5, 10 and a multipack with 2 x 5 cartridges.
Not all pack sizes may be marketed.

**Marketing Authorisation Holder**

Eli Lilly Regional Operations GmbH, Köblgasse 8-10, 1030, Vienna, Austria.

**Manufacturer**

Lilly France S.A.S., rue du Colonel Lilly, F-67640 Fegersheim, France.

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**België/Belgique/Belgien**

Eli Lilly Benelux S.A./N.V.

Tél/Tel: + 32-(0)2 548 84 84

**Lietuva**

Eli Lilly Holdings Limited atstovybe

Tel. +370 (5) 2649600

**България**

ТП "Ели Лили Нederland" Б.В. - България

tel. +359 2 491 41 40

**Magyarország**

Lilly Hungária Kft.

Tel: + 36 1 328 5100

**Česká republika**

ELI LILLY ČR, s.r.o.

Tel: + 420 234 664 111

**Malta**

Charles de Giorgio Ltd.

Tel: + 356 25600 500

**Danmark**

Eli Lilly Danmark A/S

Tlf: +45 45 26 60 00

**Nederland**

Eli Lilly Nederland B.V.

Tel: + 31-(0) 30 60 25 800

**Deutschland**

Lilly Deutschland GmbH

Tel. + 49-(0) 6172 273 2222

**Norge**

Eli Lilly Norge A.S.

Tlf: + 47 22 88 18 00

**Boehringer Ingelheim Pharma GmbH & Co. KG**

Tel: +49 (0) 800 77 90 900

**Polska**

Eli Lilly Polska Sp. z o.o.

Tel: +48 (0) 22 440 33 00

**España**

Lilly S.A.

Tel: + 34-91 663 50 00

**Österreich**

Eli Lilly Ges.m.b.H.

Tel: + 43-(0) 1 711 780

**Boehringer Ingelheim España S.A.**

Tel: +34 93 404 51 00
This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: 
HYPERGLYCAEMIA AND HYPOGLYCAEMIA

Always carry some sugar (at least 20 grams) with you.

Carry some information with you to show you are diabetic.

HYPERGLYCAEMIA (high blood sugar levels)

If your blood sugar is too high (hyperglycaemia), you may not have injected enough insulin.

Why does hyperglycaemia occur?

Examples include:
- you have not injected your insulin or not injected enough, or if it has become less effective, for example through incorrect storage,
- your insulin pen does not work properly,
- you are doing less exercise than usual, you are under stress (emotional distress, excitement), or you have an injury, operation, infection or fever,
- you are taking or have taken certain other medicines (see section 2, "Other medicines and ABASAGLAR").

Warning symptoms of hyperglycaemia
Thirst, increased need to urinate, tiredness, dry skin, reddening of the face, loss of appetite, low blood pressure, fast heartbeat, and glucose and ketone bodies in urine. Stomach pain, fast and deep breathing, sleepiness or even loss of consciousness may be signs of a serious condition (ketoacidosis) resulting from lack of insulin.

What should you do if you experience hyperglycaemia?

Test your blood sugar level and your urine for ketones as soon as any of the above symptoms occur. Severe hyperglycaemia or ketoacidosis must always be treated by a doctor, normally in a hospital.

HYPOGLYCAEMIA (low blood sugar levels)

If your blood sugar level falls too much you may become unconscious. Serious hypoglycaemia may cause a heart attack or brain damage and may be life-threatening. You normally should be able to recognise when your blood sugar is falling too much so that you can take the right actions.

Why does hypoglycaemia occur?

Examples include:
- you inject too much insulin,
- you miss meals or delay them,
- you do not eat enough, or eat food containing less carbohydrate than normal (sugar and substances similar to sugar are called carbohydrates; however, artificial sweeteners are NOT carbohydrates),
- you lose carbohydrates due to vomiting or diarrhoea,
- you drink alcohol, particularly if you are not eating much,
- you are doing more exercise than usual or a different type of physical activity,
- you are recovering from an injury or operation or other stress,
- you are recovering from an illness or from fever,
- you are taking or have stopped taking certain other medicines (see section 2, "Other medicines and ABASAGLAR").
Hypoglycaemia is also more likely to occur if

- you have just begun insulin treatment or changed to another insulin preparation (when changing from your previous basal insulin to ABASAGLAR, hypoglycaemia, if it occurs, may be more likely to occur in the morning than at night),
- your blood sugar levels are almost normal or are unstable,
- you change the area of skin where you inject insulin (for example from the thigh to the upper arm),
- you suffer from severe kidney or liver disease, or some other disease such as hypothyroidism.

Warning symptoms of hypoglycaemia

- In your body
Examples of symptoms that tell you that your blood sugar level is falling too much or too fast: sweating, clammy skin, anxiety, fast heart beat, high blood pressure, palpitations and irregular heartbeat. These symptoms often develop before the symptoms of a low sugar level in the brain.

- In your brain
Examples of symptoms that indicate a low sugar level in the brain: headaches, intense hunger, nausea, vomiting, tiredness, sleepiness, sleep disturbances, restlessness, aggressive behaviour, lapses in concentration, impaired reactions, depression, confusion, speech disturbances (sometimes total loss of speech), visual disorders, trembling, paralysis, tingling sensations (paraesthesia), numbness and tingling sensations in the area of the mouth, dizziness, loss of self-control, inability to look after yourself, convulsions, loss of consciousness.

The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if
- you are elderly, if you have had diabetes for a long time or if you suffer from a certain type of nervous disease (diabetic autonomic neuropathy),
- you have recently suffered hypoglycaemia (for example the day before) or if it develops slowly,
- you have almost normal or, at least, greatly improved blood sugar levels,
- you have recently changed from an animal insulin to a human insulin such as ABASAGLAR,
- you are taking or have taken certain other medicines (see section 2, "Other medicines and ABASAGLAR").

In such a case, you may develop severe hypoglycaemia (and even faint) before you are aware of the problem. Be familiar with your warning symptoms. If necessary, more frequent blood sugar testing can help to identify mild hypoglycaemic episodes that may otherwise be overlooked. If you are not confident about recognising your warning symptoms, avoid situations (such as driving a car) in which you or others would be put at risk by hypoglycaemia.

What should you do if you experience hypoglycaemia?

1. Do not inject insulin. Immediately take about 10 to 20 g sugar, such as glucose, sugar cubes or a sugar-sweetened beverage. Caution: Artificial sweeteners and foods with artificial sweeteners (such as diet drinks) are of no help in treating hypoglycaemia.

2. Then eat something that has a long-acting effect in raising your blood sugar (such as bread or pasta). Your doctor or nurse should have discussed this with you previously.

   The recovery of hypoglycaemia may be delayed because ABASAGLAR has a long action.'

3. If the hypoglycaemia comes back again, take another 10 to 20 g sugar.

4. Speak to a doctor immediately if you are not able to control the hypoglycaemia or if it recurs. Tell your relatives, friends and close colleagues the following:

   If you are not able to swallow or if you are unconscious, you will require an injection of glucose or glucagon (a medicine which increases blood sugar). These injections are justified even if it is not certain that you have hypoglycaemia.
It is advisable to test your blood sugar immediately after taking glucose to check that you really have hypoglycaemia.
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully including the Instructions for Use of the ABASAGLAR KwikPen pre-filled pen, before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What ABASAGLAR is and what it is used for
2. What you need to know before you use ABASAGLAR
3. How to use ABASAGLAR
4. Possible side effects
5. How to store ABASAGLAR
6. Contents of the pack and other information

1. What ABASAGLAR is and what it is used for

ABASAGLAR is a solution for injection containing insulin glargine. Insulin glargine is a modified insulin, very similar to human insulin.

ABASAGLAR is used to treat diabetes mellitus in adults, adolescents and children aged 2 years and above.

Diabetes mellitus is a disease where your body does not produce enough insulin to control the level of blood sugar. Insulin glargine has a long and steady blood-sugar-lowering action.

2. What you need to know before you use ABASAGLAR

Do not use ABASAGLAR

If you are allergic to insulin glargine or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist or nurse before using ABASAGLAR. Follow closely the instructions for posology, monitoring (blood and urine tests), diet and physical activity (physical work and exercise) as discussed with your doctor.

If your blood sugar is too low (hypoglycaemia), follow the guidance for hypoglycaemia (see box at the end of this leaflet).
Travel
Before travelling consult your doctor. You may need to talk about:
- the availability of your insulin in the country you are visiting,
- supplies of insulin, syringes etc.,
- correct storage of your insulin while travelling,
- timing of meals and insulin administration while travelling,
- the possible effects of changing to different time zones,
- possible new health risks in the countries to be visited,
- what you should do in emergency situations when you feel unwell or become ill.

Illnesses and injuries
In the following situations, the management of your diabetes may require a lot of care (for example, adjustment to insulin dose, blood and urine tests):
- If you are ill or have a major injury then your blood sugar level may increase (hyperglycaemia).
- If you are not eating enough your blood sugar level may become too low (hypoglycaemia).
In most cases you will need a doctor. Make sure that you contact a doctor early.

If you have type 1 diabetes (insulin dependent diabetes mellitus), do not stop your insulin and continue to get enough carbohydrates. Always tell people who are caring for you or treating you that you require insulin.

Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).

Other medicines and ABASAGLAR
Some medicines cause changes in the blood sugar level (decrease, increase or both depending on the situation). In each case, it may be necessary to adjust your insulin dose to avoid blood sugar levels that are either too low or too high. Be careful when you start or stop taking another medicine. Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Before taking a medicine ask your doctor if it can affect your blood sugar level and what action, if any, you need to take.

Medicines that may cause your blood sugar level to fall (hypoglycaemia) include:
- all other medicines to treat diabetes,
- angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure),
- disopyramide (used to treat certain heart conditions),
- fluoxetine (used to treat depression),
- fibrates (used to lower high levels of blood lipids),
- monoamine oxidase (MAO) inhibitors (used to treat depression),
- pentoxyfylline, propoxyphene, salicylates (such as aspirin, used to relieve pain and lower fever),
- somatostatin analogues (such as octreotide, used to treat an uncommon condition in which you make too much growth hormone),
- sulphonamide antibiotics.

Medicines that may cause your blood sugar level to rise (hyperglycaemia) include:
- corticosteroids (such as "cortisone" used to treat inflammation),
- danazol (medicine acting on ovulation),
- diazoxide (used to treat high blood pressure),
- diuretics (used to treat high blood pressure or excessive fluid retention),
- glucagon (pancreas hormone used to treat severe hypoglycaemia),
- isoniazid (used to treat tuberculosis),
- oestrogens and progestogens (such as in the contraceptive pill used for birth control),
- phenothiazine derivatives (used to treat psychiatric disorders),
- somatropin (growth hormone),
- sympathomimetic medicines (such as epinephrine [adrenaline], salbutamol, terbutaline used to treat asthma),
- thyroid hormones (used to treat thyroid gland disorders),
- atypical antipsychotic medicines (such as clozapine, olanzapine),
- protease inhibitors (used to treat HIV).

Your blood sugar level may either rise or fall if you take:

- beta-blockers (used to treat high blood pressure),
- clonidine (used to treat high blood pressure),
- lithium salts (used to treat psychiatric disorders).

Pentamidine (used to treat some infections caused by parasites) may cause hypoglycaemia which may sometimes be followed by hyperglycaemia.

Beta-blockers like other sympatholytic medicines (such as clonidine, guanethidine, and reserpine) may weaken or suppress entirely the first warning symptoms which help you to recognise a hypoglycaemia. If you are not sure whether you are taking one of those medicines ask your doctor or pharmacist.

**ABASAGLAR with alcohol**

Your blood sugar levels may either rise or fall if you drink alcohol.

**Pregnancy and breast-feeding**

Ask your doctor or pharmacist for advice before taking any medicine. Inform your doctor if you are planning to become pregnant, or if you are already pregnant. Your insulin dose may need to be changed during pregnancy and after giving birth. Particularly careful control of your diabetes, and prevention of hypoglycaemia, is important for the health of your baby. If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet.

**Driving and using machines**

Your ability to concentrate or react may be reduced if:

- you have hypoglycaemia (low blood sugar levels),
- you have hyperglycaemia (high blood sugar levels),
- you have problems with your sight.

Keep this possible problem in mind in all situations where you might put yourself and others at risk (such as driving a car or operating machines). You should contact your doctor for advice on driving if:

- you have frequent episodes of hypoglycaemia,
- the first warning symptoms which help you to recognise hypoglycaemia are reduced or absent.

**Important information about some of the ingredients of ABASAGLAR**

This medicine contains less than 1 mmol (23 mg) sodium per dose, which means it is essentially ‘sodium-free’.

**3. How to use ABASAGLAR**

Always use this medicine exactly as you doctor has told you. Check with your doctor or pharmacist if you are not sure.
Dose

Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will:

- determine how much ABASAGLAR per day you will need and at what time,
- tell you when to check your blood sugar level, and whether you need to carry out urine tests,
- tell you when you may need to inject a higher or lower dose of ABASAGLAR.

ABASAGLAR is a long-acting insulin. Your doctor may tell you to use it in combination with a short-acting insulin or with tablets used to treat high blood sugar levels.

Many factors may influence your blood sugar level. You should know these factors so that you are able to react correctly to changes in your blood sugar level and to prevent it from becoming too high or too low. See the box at the end of this leaflet for further information.

Use in children and adolescents

ABASAGLAR can be used in adolescents and children aged 2 years and above. There is no experience with the use of ABASAGLAR in children below the age of 2 years.

Frequency of administration

You need one injection of ABASAGLAR every day, at the same time of the day.

Method of administration

ABASAGLAR is injected under the skin. Do NOT inject ABASAGLAR in a vein, since this will change its action and may cause hypoglycaemia.

Your doctor will show you in which area of the skin you should inject ABASAGLAR. With each injection, change the puncture site within the particular area of skin that you are using.

How to handle ABASAGLAR KwikPen

ABASAGLAR KwikPen is a pre-filled disposable pen containing insulin glargine.

Read carefully the "ABASAGLAR KwikPen Instructions for Use" included with this package leaflet. You must use the pen as described in these Instructions for Use.

A new needle must be attached before each use. Only use needles that are compatible for use with ABASAGLAR KwikPen (see “ABASAGLAR KwikPen Instructions for Use”).

A safety test must be performed before each injection.

Look at the cartridge before you use the pen. Do not use ABASAGLAR KwikPen if you notice particles in it. Only use ABASAGLAR KwikPen if the solution is clear, colourless and water-like. Do not shake or mix it before use.

To prevent the possible transmission of disease, each pen must be used by one patient only.

Make sure that neither alcohol nor other disinfectants or other substances contaminate the insulin.

Always use a new pen if you notice that your blood sugar control is unexpectedly getting worse. If you think you may have a problem with ABASAGLAR KwikPen, consult your doctor, pharmacist or nurse.
Empty pens must not be re-filled and must be properly discarded.

Do not use ABASAGLAR KwikPen if it is damaged or not working properly, it has to be discarded and a new KwikPen has to be used.

If you use more ABASAGLAR than you should
- If you have injected too much ABASAGLAR, your blood sugar level may become too low (hypoglycaemia). Check your blood sugar frequently. In general, to prevent hypoglycaemia you must eat more food and monitor your blood sugar. For information on the treatment of hypoglycaemia, see box at the end of this leaflet.

If you forget to use ABASAGLAR
- If you have missed a dose of ABASAGLAR or if you have not injected enough insulin, your blood sugar level may become too high (hyperglycaemia). Check your blood sugar frequently. For information on the treatment of hyperglycaemia, see box at the end of this leaflet.
- Do not take a double dose to make up for a forgotten dose.

If you stop using ABASAGLAR

This could lead to severe hyperglycaemia (very high blood sugar) and ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar). Do not stop ABASAGLAR without speaking to a doctor, who will tell you what needs to be done.

Insulin Mix-ups

You must always check the insulin label before each injection to avoid mix-ups between ABASAGLAR and other insulins.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Hypoglycaemia (low blood sugar) can be very serious. If your blood sugar level falls too much you may become unconscious. Serious hypoglycaemia may cause brain damage and may be life-threatening. If you have symptoms of low blood sugar, take actions to increase your blood sugar level immediately.

If you experience the following symptoms, contact your doctor immediately: large-scale skin reactions (rash and itching all over the body), severe swelling of skin or mucous membranes (angiooedema), shortness of breath, a fall in blood pressure with rapid heartbeat and sweating. These could be symptoms of severe allergic reactions to insulins and may become life threatening.

Very common side effects (may affect more than 1 in 10 people)
- Hypoglycaemia

As with all insulin therapy, the most frequent side effect is hypoglycaemia.

Hypoglycaemia (low blood sugar) means that there is not enough sugar in the blood. For further information on the side effects of low blood sugar or high blood sugar, see the box at the end of this leaflet.
Common side effects (may affect up to 1 in 10 people)

- **Skin changes at the injection site**

  If you inject your insulin too often at the same skin site, fatty tissue under the skin at this site may either shrink (lipoatrophy) or thicken (lipohypertrophy). Thickening of fatty tissue may occur in 1 to 2% of patients while shrinking may occur uncommonly. Insulin that you inject in such a site may not work very well. Changing the injection site with each injection may help to prevent such skin changes.

- **Skin and allergic reactions**

  3 to 4% of patients may experience reactions at the injection site (such as reddening, unusually intense pain on injection, itching, hives, swelling or inflammation). They can also spread around the injection site. Most minor reactions to insulins usually resolve in a few days to a few weeks.

**Rare side effects** (may affect up to 1 in 1,000 people)

- **Severe allergic reactions to insulins**

  Associated symptoms may include large-scale skin reactions (rash and itching all over the body), severe swelling of skin or mucous membranes (angioedema), shortness of breath, a fall in blood pressure with rapid heartbeat and sweating. These could be symptoms of severe allergic reactions to insulins and may become life-threatening.

- **Eye reactions**

  A marked change (improvement or worsening) in your blood sugar control can disturb your vision temporarily. If you have proliferative retinopathy (an eye disease related to diabetes) severe hypoglycaemic attacks may cause temporary loss of vision.

- **General disorders**

  In rare cases, insulin treatment may also cause temporary build-up of water in the body, with swelling in the calves and ankles.

**Very rare side-effects** (may affect up to 1 in 10,000 people)

  In very rare cases, dysgeusia (taste disorders) and myalgia (muscular pain) can occur.

**Other side effects with frequency not known** (frequency cannot be estimated from available data)

  Insulin treatment can cause the body to produce antibodies to insulin (substances that act against insulin). Rarely, this may require a change to your insulin dose.

**Use in children and adolescents**

  In general, the side effects in children and adolescents of 18 years of age or less are similar to those seen in adults.

  Complaints of injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) are reported relatively more frequently in children and adolescents of 18 years of age or less than in adults.

  Clinical study safety data are not available for children under 2 years.

**Reporting of side effects**

  If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system.
listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store ABASAGLAR

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the label of the pen after “EXP”. The expiry date refers to the last day of that month.

Not in-use pens
Store in a refrigerator (2°C - 8°C). Do not freeze.
Do not put ABASAGLAR next to the freezer compartment or a freezer pack.
Keep the pre-filled pen in the outer carton in order to protect from light.

In-use pens
Pre-filled pens in use or carried as a spare may be stored for a maximum of 28 days up to 30°C and away from direct heat or direct light. The pen in use must not be stored in the refrigerator. Do not use it after this time period. The pen cap must be put back on the pen after each injection in order to protect from light.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What ABASAGLAR contains

- The active substance is insulin glargine. Each millilitre of the solution contains 100 units of the active substance insulin glargine (equivalent to 3.64 mg).
- The other ingredients are: zinc oxide, metacresol, glycerol, sodium hydroxide (see section 2 “Important information about some of the ingredients of ABASAGLAR”), hydrochloric acid and water for injections.

What ABASAGLAR looks like and contents of the pack

ABASAGLAR 100 units/mL solution for injection in a pre-filled pen, KwikPen, is a clear and colourless solution.

Each pen contains 3 mL of solution for injection (equivalent to 300 units). Packs of 1, 2, 5 and a multipack with 2 x 5 pre-filled pens of 3 mL are available.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Eli Lilly Regional Operations GmbH., Köblbgasse 8-10, 1030, Vienna, Austria.

Manufacturer

Lilly France S.A.S., rue du Colonel Lilly, F-67640 Fegersheim, France.

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
België/Belgique/Belgien
Eli Lilly Benelux S.A./N.V.
Tél/Tel: + 32-(0)2 548 84 84

Lietuva
Eli Lilly Holdings Limited atstovybe
Tel. +370 (5) 2649600

България
ТП “Ели Лили Нederland” Б.В. - България
tel. +359 2 491 41 40

Magyarország
Lilly Hungária Kft.
Tel: + 36 1 328 5100

Česká republika
ELI LILLY ČR, s.r.o.
Tel: + 420 234 664 111

Luxembourg/Luxemburg
Eli Lilly Benelux S.A./N.V.
Tél/Tel: + 32-(0)2 548 84 84

Danmark
Eli Lilly Danmark A/S
Tlf: +45 45 26 60 00

Österreich
Eli Lilly Ges.m.b.H.
Tel: + 43-(0) 1 711 780

Deutschland
Lilly Deutschland GmbH
Tel. + 49-(0) 6172 273 2222

Eesti
Eli Lilly Holdings Limited Eesti filiaal
Tel: +372 6 817 280

Portugal
Lilly Portugal Produtos Farmacêuticos, Lda
Tel: + 351-21-4126600

España
Lilly S.A.
Tel: + 34-91 663 50 00

Boehringer Ingelheim Pharma GmbH & Co. KG
Tel: +49 (0) 800 77 90 900

Boehringer Ingelheim España S.A.
Tel: +34 93 404 51 00

Norge
Eli Lilly Norge A.S.
Tlf: + 47 22 88 18 00

Ελλάδα
ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ Α.Ε.Β.Ε.
Τηλ: +30 210 629 4600

Österreich
Eli Lilly Ges.m.b.H.
Tel: + 43-(0) 1 711 780

Bulgaria
ТП “Ели Лили Нederland” Б.В. - България
tel. +359 2 491 41 40

Polska
Eli Lilly Polska Sp. z o.o.
Tel: +48 (0) 22 440 33 00

Hrvatska
Eli Lilly Hrvatska d.o.o.
Tel: +385 1 2350 999

România
Eli Lilly România S.R.L.
Tel: + 40 21 4023000

Ireland
Eli Lilly and Company (Ireland) Limited
Tel: + 353-(0) 1 661 4377

Slovenija
Eli Lilly farmacevtska družba, d.o.o.
Tel: +386 (0)1 580 00 10

Boehringer Ingelheim Ireland Ltd.
Tel: +353 1 295 9620
This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
HYPERGLYCAEMIA AND HYPOGLYCAEMIA

Always carry some sugar (at least 20 grams) with you.

Carry some information with you to show you are diabetic.

HYPERGLYCAEMIA (high blood sugar levels)

If your blood sugar is too high (hyperglycaemia), you may not have injected enough insulin.

Why does hyperglycaemia occur?

Examples include:
- you have not injected your insulin or not injected enough, or if it has become less effective, for example through incorrect storage,
- your insulin pen does not work properly,
- you are doing less exercise than usual, you are under stress (emotional distress, excitement), or you have an injury, operation, infection or fever,
- you are taking or have taken certain other medicines (see section 2, "Other medicines and ABASAGLAR”).

Warning symptoms of hyperglycaemia
Thirst, increased need to urinate, tiredness, dry skin, reddening of the face, loss of appetite, low blood pressure, fast heartbeat, and glucose and ketone bodies in urine. Stomach pain, fast and deep breathing, sleepiness or even loss of consciousness may be signs of a serious condition (ketoacidosis) resulting from lack of insulin.

What should you do if you experience hyperglycaemia?

Test your blood sugar level and your urine for ketones as soon as any of the above symptoms occur. Severe hyperglycaemia or ketoacidosis must always be treated by a doctor, normally in a hospital.

HYPOGLYCAEMIA (low blood sugar levels)

If your blood sugar level falls too much you may become unconscious. Serious hypoglycaemia may cause a heart attack or brain damage and may be life-threatening. You normally should be able to recognise when your blood sugar is falling too much so that you can take the right actions.

Why does hypoglycaemia occur?

Examples include:
- you inject too much insulin,
- you miss meals or delay them,
- you do not eat enough, or eat food containing less carbohydrate than normal (sugar and substances similar to sugar are called carbohydrates; however, artificial sweeteners are NOT carbohydrates),
- you lose carbohydrates due to vomiting or diarrhoea,
- you drink alcohol, particularly if you are not eating much,
- you are doing more exercise than usual or a different type of physical activity,
- you are recovering from an injury or operation or other stress,
- you are recovering from an illness or from fever,
- you are taking or have stopped taking certain other medicines (see section 2, "Other medicines and ABASAGLAR”).
Hypoglycaemia is also more likely to occur if
- you have just begun insulin treatment or changed to another insulin preparation (when changing from your previous basal insulin to ABASAGLAR, hypoglycaemia, if it occurs, may be more likely to occur in the morning than at night),
- your blood sugar levels are almost normal or are unstable,
- you change the area of skin where you inject insulin (for example from the thigh to the upper arm),
- you suffer from severe kidney or liver disease, or some other disease such as hypothyroidism.

Warning symptoms of hypoglycaemia

- In your body
Examples of symptoms that tell you that your blood sugar level is falling too much or too fast: sweating, clammy skin, anxiety, fast heart beat, high blood pressure, palpitations and irregular heartbeat. These symptoms often develop before the symptoms of a low sugar level in the brain.

- In your brain
Examples of symptoms that indicate a low sugar level in the brain: headaches, intense hunger, nausea, vomiting, tiredness, sleepiness, sleep disturbances, restlessness, aggressive behaviour, lapses in concentration, impaired reactions, depression, confusion, speech disturbances (sometimes total loss of speech), visual disorders, trembling, paralysis, tingling sensations (paraesthesia), numbness and tingling sensations in the area of the mouth, dizziness, loss of self-control, inability to look after yourself, convulsions, loss of consciousness.

The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if
- you are elderly, if you have had diabetes for a long time or if you suffer from a certain type of nervous disease (diabetic autonomic neuropathy),
- you have recently suffered hypoglycaemia (for example the day before) or if it develops slowly,
- you have almost normal or, at least, greatly improved blood sugar levels,
- you have recently changed from an animal insulin to a human insulin such as ABASAGLAR,
- you are taking or have taken certain other medicines (see section 2, "Other medicines and ABASAGLAR").

In such a case, you may develop severe hypoglycaemia (and even faint) before you are aware of the problem. Be familiar with your warning symptoms. If necessary, more frequent blood sugar testing can help to identify mild hypoglycaemic episodes that may otherwise be overlooked. If you are not confident about recognising your warning symptoms, avoid situations (such as driving a car) in which you or others would be put at risk by hypoglycaemia.

What should you do if you experience hypoglycaemia?

1. Do not inject insulin. Immediately take about 10 to 20 g sugar, such as glucose, sugar cubes or a sugar-sweetened beverage. Caution: Artificial sweeteners and foods with artificial sweeteners (such as diet drinks) are of no help in treating hypoglycaemia.

2. Then eat something that has a long-acting effect in raising your blood sugar (such as bread or pasta). Your doctor or nurse should have discussed this with you previously.

   The recovery of hypoglycaemia may be delayed because ABASAGLAR has a long action.’

3. If the hypoglycaemia comes back again, take another 10 to 20 g sugar.

4. Speak to a doctor immediately if you are not able to control the hypoglycaemia or if it recurs. Tell your relatives, friends and close colleagues the following:

   If you are not able to swallow or if you are unconscious, you will require an injection of glucose or glucagon (a medicine which increases blood sugar). These injections are justified even if it is not certain that you have hypoglycaemia.
It is advisable to test your blood sugar immediately after taking glucose to check that you really have hypoglycaemia.
Instructions for use
KwikPen
ABASAGLAR 100 units/mL solution for injection in a pre-filled pen
Insulin glargine

PLEASE READ THESE INSTRUCTIONS BEFORE USE

Read the instructions for use before you start taking ABASAGLAR and each time you get another ABASAGLAR KwikPen. There may be new information. This information does not take the place of talking to your healthcare professional about your medical condition or your treatment.

ABASAGLAR KwikPen (“Pen”) is a disposable pen containing 300 units (3 mL) of insulin glargine. You can give yourself multiple doses using one pen. The pen dials 1 unit at a time. You can give from 1 to 60 80 units in a single injection. If your dose is more than 60 80 units, you will need to give yourself more than one injection. The plunger only moves a little with each injection and you may not notice that it moves. The plunger will only reach the end of the cartridge when you have used all 300 units in the pen.

Do not share your pen with other people, even if the needle has been changed. Do not reuse or share needles with other people. You may give an infection to them or get an infection from them.

This pen is not recommended for use by the blind or visually impaired without the help of someone trained to use the pen.

KwikPen Parts

Pen Cap
Cartridge Holder
Label
Dose Indicator

Cap Clip
Rubber Seal
Plunger
Pen Body
Dose Window
Dose Knob

Pen Needle Parts ( Needles Not Included)

Needle

Outer Needle Shield
Inner Needle Shield
Paper Tab

Dose Knob with green ring
How to recognise your ABASAGLAR KwikPen:
- Pen colour: Light grey
- Dose Knob: Light grey with green ring on the end
- Labels: Light grey with green colour bars

Supplies needed to give your injection:
- ABASAGLAR KwikPen
- Swab

Preparing your Pen
- Wash your hands with soap and water
- Check the pen to make sure you are taking the right type of insulin. This is especially important if you use more than 1 type of insulin.
- **Do not** use your pen past the expiration date printed on the label or for more than 28 days after you first start using the pen.
- Always use a **new needle** for each injection to help prevent infections and blocked needles.

### Step 1:
- Pull the pen cap straight off.
  - Do not remove the pen label.
- Wipe the rubber seal with a swab.

ABASAGLAR should look clear and colourless. **Do not** use if it is cloudy, coloured, or has particles or clumps in it.

### Step 2:
- Select a new needle.
- Pull off the paper tab from the outer needle shield.

### Step 3:
- Push the capped needle straight onto the pen and twist the needle on until it is tight.

### Step 4:
- Pull off the outer needle shield. **Do not** throw it away.
- Pull off the inner needle shield and throw it away.
Priming your pen
Prime before each injection.
- Priming your pen means removing the air from the needle and cartridge that may collect during normal use and ensures that the pen is working correctly.
- If you **do not** prime before each injection, you may get too much or too little insulin.

<table>
<thead>
<tr>
<th>Step 5:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• To prime your pen, turn the dose knob to select 2 units.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Step 6:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Hold your pen with the needle pointing up. Tap the cartridge holder gently to collect air bubbles at the top.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Step 7:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Continue holding your pen with needle pointing up. Push the dose knob in until it stops, and “0” is seen in the dose window. Hold the dose knob in and count to 5 slowly. You should see insulin at the tip of the needle.</td>
</tr>
<tr>
<td>- If you <strong>do not</strong> see insulin, repeat the priming steps, but not more than 4 times.</td>
</tr>
<tr>
<td>- If you <strong>still do not</strong> see insulin, change the needle and repeat the priming steps.</td>
</tr>
</tbody>
</table>

Small air bubbles are normal and will not affect your dose.

Selecting your dose
- You can give from 1 to 6080 units in a single injection.
- If your dose is more than 6080 units, you will need to give more than one injection.
  - If you need help deciding how to divide up your dose, ask your healthcare professional.
  - You should use a new needle for each injection and repeat the priming step.
Step 8:

- Turn the dose knob to select the number of units you need to inject. The dose indicator should line up with your dose.
  - The pen dials 1 unit at a time.
  - The dose knob clicks as you turn it.
  - DO NOT dial your dose by counting the clicks because you may dial the wrong dose.
  - The dose can be corrected by turning the dose knob in either direction until the correct dose lines up with the dose indicator.
  - The even numbers are printed on the dial.

- The odd numbers, after the number 1, are shown as full lines.

- Always check the number in the Dose Window to make sure you have dialled the correct dose.

- The pen will not let you dial more than the number of units left in the pen.
- If you need to inject more than the number of units left in the pen, you may either:
  - inject the amount left in your pen and then use a new pen to give the rest of your dose, or
  - get a new pen and inject the full dose.
- It is normal to see a small amount of insulin left in the pen that you cannot inject.

Giving your injection

- Inject your insulin as your healthcare professional has shown you.
- Change (rotate) your injection site for each injection.
- Do not try to change your dose while injecting.
Step 9:
Choose your injection site.

- ABASAGLAR is injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs or upper arms.
- Prepare your skin as recommended by your healthcare professional.

Step 10:
- Insert the needle into your skin.
- Push the dose knob all the way in
- Continue to hold the dose knob in and **slowly count** to 5 before removing the needle.

**Do not** try to inject your insulin by turning the dose knob. You will **NOT** receive your insulin by turning the dose knob.

Step 11:
- Pull the needle out of your skin.
  
  - A drop of insulin at the needle tip is normal. It will not affect your dose.

- Check the number in the dose window
  
  - If you see “0” in the dose window, you have received the full amount you dialled.
  - If you do not see “0” in the dose window, **do not** redial. Insert the needle into your skin and finish your injection.
  - If you **still** do not think you received the full amount you dialled for your injection, **do not start over or repeat that injection.**
  
  Monitor your blood glucose as instructed by your healthcare professional.

  - If you normally need to give 2 injections for your full dose, be sure to give your second injection.

The plunger only moves a little with each injection and you may not notice that it moves.

If you see blood after you take the needle out of your skin, press the injection site lightly with a piece of gauze or swab. **Do not** rub the area.
After your injection

**Step 12:**
- Carefully replace the outer needle shield.

**Step 13:**
- Unscrew the capped needle and dispose of it as directed by your healthcare professional.
- Do not store the pen with the needle attached to prevent leaking, blocking the needle, and air from entering the pen.

**Step 14:**
- Replace the pen cap by lining up the cap clip with the dose indicator and pushing straight on.

Disposing of pens and needles
- Put used needles in a closable, puncture-resistant sharps container.
- Do not recycle the filled sharps container.
- Ask your healthcare professional about options to dispose of the pens and sharps container properly.
- The directions regarding needle handling are not intended to replace local, healthcare professional or institutional policies.

Storing your pen

**Unused pens**
- Store unused pens in the refrigerator at 2 °C to 8 °C.
- **Do not** freeze ABASAGLAR. **Do not** use if it has been frozen.
- Unused pens may be used until the expiration date printed on the label, if the pen has been kept in the refrigerator.

**In-use pen**
- Store the pen you are currently using at room temperature [below 30 °C] and away from heat and light.
- Throw away the pen you are using after 28 days, even if it still has insulin left in it.

General information about the safe and effective use of your pen
- **Keep your pen and needles out of the sight and reach of children.**
- **Do not** use your pen if any part looks broken or damaged.
- Always carry an extra pen in case yours is lost or damaged.
Troubleshooting

- If you cannot remove the pen cap, gently twist the cap back and forth, and then pull the cap straight off.
- If the dose knob is hard to push:
  - Pushing the dose knob more slowly will make it easier to inject.
  - Your needle may be blocked. Put on a new needle and prime the pen.
  - You may have dust, food, or liquid inside the pen. Throw the pen away and get a new pen.

If you have any questions or problems with your ABASAGLAR KwikPen, contact your healthcare professional for assistance.

This leaflet was last revised in <{MM/YYY}> <{month YYYY}>.